Recent Press Releases

Biopharmaceutical industry files complaint against French law promoting government-initiated off-label use without the involvement or consent of patients and their physicians

Biopharmaceutical industry files complaint against French law promoting government-initiated off-label use without the involvement or consent of patients and their physicians The European Federation...

Mylan Confirms the U.S. Patent and Trademark Office Institutes Inter Partes Review Proceeding against Third Copaxone(R) 40 mg/mL Dosing Patent on All Claims

HERTFORDSHIRE, England and PITTSBURGH, Sept. 2, 2015 /PRNewswire/ -- Mylan N.V. (Nasdaq: MYL) today announced that the U.S. Patent and Trademark Office (PTO) has instituted an inter partes review...

LEO Pharma announces new global leadership

LEO Pharma, a global healthcare company dedicated to helping people achieve healthy skin, announces a new global leadership structure and team to support its efforts to help more than 70 million...

New Global Real-World Data from Atrial Fibrillation Studies Confirm the Safety Profile of XARELTO®

LONDON, Sept. 1, 2015 /PRNewswire/ -- Janssen Pharmaceuticals, Inc., and its development partner, Bayer HealthCare, today announced results from PMSS (Post-Marketing Safety Surveillance) and XANTUS...

Novartis receives EU approval for Tafinlar and Mekinist, first combination approved for patients with aggressive form of melanoma

Novartis receives EU approval for Tafinlar and Mekinist, first combination approved for patients with aggressive form of melanoma TUESDAY, 1 SEPTEMBER 2015 - 8:15AM Approval based on two Phase III...

Teva Announces U.S. Availability of ZECUITY(R) (sumatriptan iontophoretic transdermal system), First and Only Transdermal Patch System for the Acute Treatment of Migraine

JERUSALEM--(BUSINESS WIRE)--Sep. 1, 2015-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced that ZECUITY®, the first and only patch system designed to provide relief from migraine,...

Novartis receives EU approval for Tafinlar® and Mekinist®, first combination approved for patients with aggressive form of melanoma

Approval based on two Phase III studies demonstrating statistically significant overall survival benefit with combination therapy vs BRAF inhibitor monotherapy Targeted combination offers BRAF V600...

PEGASUS-TIMI 54 SUB-ANALYSIS SHOWS IMPORTANCE OF CONTINUING TREATMENT WITH BRILINTA BEYOND ONE YEAR FOLLOWING A HEART ATTACK

Data presented at ESC Congress 2015 reinforce the need for long-term secondary prevention of cardiovascular events 31 August 2015 AstraZeneca today announced details of a sub-analysis of the...

ELIXA Trial Shows CV Safety of Lixisenatide

In patients with type 2 diabetes and acute coronary syndrome, the glucose-lowering medication lixisenatide did not increase or decrease the rate of cardiovascular (CV) events compared to placebo,...

Allergan Successfully Completes Naurex Acquisition

- Two Lead Development Products Rapastinel (GLYX-13) and NRX-1074 Demonstrated Rapid Onset of Action and Robust Efficacy in Phase 2 Studies in Major Depressive Disorder - - Adds Potential...

New TECOS Analysis Adds Heart Failure Data For Sitagliptin

Patients with type-2 diabetes and cardiovascular disease can safely take the antihyperglycemic drug sitagliptin without an increased risk of cardiovascular complications - even if they have a history...

Patient Education Does Not Impact Apixaban Adherence

Patient Education Does Not Impact Apixaban Adherence Adherence to the oral anticoagulant apixaban among patients with atrial fibrillation (AF) was no better for those who received an educational...

Celgene Completes Acquisition of Receptos, Advancing Leadership in Immune-Inflammatory Diseases

SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (CELG) today announced it has closed its acquisition of Receptos, Inc. Receptos stockholders received $232.00 per share in cash, for a total of...

Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction

Offer Substantially Undervalues Perrigo, Exposes Shareholders to Risk and Mylan's Weak Business Prospects Value Destructive Transaction Would Be Highly Dilutive to EPS and Perrigo's Growth...

Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo

Mylan Intends to Launch Formal Offer to Perrigo Shareholders in the Coming Weeks HERTFORDSHIRE, England and PITTSBURGH, Aug. 28, 2015 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced that its...

Alliance Foundation Trials and Austrian Breast & Colorectal Cancer Study Group Open Largest Global Phase 3 Trial of Targeted Therapy, IBRANCE® (palbociclib), for Patients with Hormone Receptor–Positive Early Breast Cancer

NEW YORK--(BUSINESS WIRE)--The Alliance Foundation Trials, LLC (AFT), the Austrian Breast & Colorectal Cancer Study Group (ABCSG) and Pfizer Inc. today announced the launch of the Palbociclib...

U.S. District Court Rules in Lilly's Favor on Alimta Vitamin Regimen Patent

U.S. District Court Rules in Lilly's Favor on Alimta Vitamin Regimen Patent INDIANAPOLIS, Aug. 25, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. District...

SUCAMPO LAUNCHES TENDER OFFER TO ACQUIRE R-TECH UENO

Acquisition Expected to be Immediately Accretive Advances Sucampo Strategy to Strengthen Financial Performance and Diversify Pipeline Acquisition Expected to Close in Q4 2015 Company to Host...

Mylan Comments on Misleading Statements Made by Perrigo

HERTFORDSHIRE, England and PITTSBURGH, Aug. 25, 2015 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today commented on the misleading statements made by Perrigo Company plc (NYSE: PRGO; TASE) in relation...

Shire to Attain Enhanced CINRYZE® Manufacturing Flexibility and Capacity

Shire to Attain Enhanced CINRYZE® Manufacturing Flexibility and Capacity The company enters into new agreement with Sanquin Lexington, Mass. – August 25, 2015 – Shire plc (LSE: SHP,...